CN101848896A - 作为组胺-3拮抗剂的异喹啉基和异吲哚啉基衍生物 - Google Patents

作为组胺-3拮抗剂的异喹啉基和异吲哚啉基衍生物 Download PDF

Info

Publication number
CN101848896A
CN101848896A CN200880106892A CN200880106892A CN101848896A CN 101848896 A CN101848896 A CN 101848896A CN 200880106892 A CN200880106892 A CN 200880106892A CN 200880106892 A CN200880106892 A CN 200880106892A CN 101848896 A CN101848896 A CN 101848896A
Authority
CN
China
Prior art keywords
pyrrolidin
ylethyl
oxo
ethyl
methylpyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880106892A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·格罗斯
A·J·罗比肖
D·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101848896A publication Critical patent/CN101848896A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN200880106892A 2007-09-12 2008-09-11 作为组胺-3拮抗剂的异喹啉基和异吲哚啉基衍生物 Pending CN101848896A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99363607P 2007-09-12 2007-09-12
US60/993,636 2007-09-12
PCT/US2008/075981 WO2009036144A1 (en) 2007-09-12 2008-09-11 Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists

Publications (1)

Publication Number Publication Date
CN101848896A true CN101848896A (zh) 2010-09-29

Family

ID=40261509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880106892A Pending CN101848896A (zh) 2007-09-12 2008-09-11 作为组胺-3拮抗剂的异喹啉基和异吲哚啉基衍生物

Country Status (25)

Country Link
US (1) US20090069300A1 (https=)
EP (1) EP2200989A1 (https=)
JP (1) JP2010539180A (https=)
KR (1) KR20100054856A (https=)
CN (1) CN101848896A (https=)
AP (1) AP2010005202A0 (https=)
AR (1) AR068423A1 (https=)
AU (1) AU2008298926A1 (https=)
BR (1) BRPI0817061A2 (https=)
CA (1) CA2699384A1 (https=)
CL (1) CL2008002726A1 (https=)
CO (1) CO6300955A2 (https=)
CR (1) CR11303A (https=)
DO (1) DOP2010000079A (https=)
EA (1) EA201000316A1 (https=)
EC (1) ECSP10010025A (https=)
MA (1) MA31699B1 (https=)
MX (1) MX2010002760A (https=)
NI (1) NI201000036A (https=)
PA (1) PA8795701A1 (https=)
PE (1) PE20090651A1 (https=)
TN (1) TN2010000105A1 (https=)
TW (1) TW200927114A (https=)
WO (1) WO2009036144A1 (https=)
ZA (1) ZA201001751B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103649056A (zh) * 2011-05-10 2014-03-19 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
CN105254554A (zh) * 2014-07-14 2016-01-20 南开大学 一种制备异吲哚啉酮类化合物的方法
CN115551593A (zh) * 2020-04-08 2022-12-30 雷密克斯医疗公司 用于调节剪接的化合物和方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
US8952034B2 (en) * 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
EP2632461A4 (en) * 2010-10-29 2014-04-02 Merck Sharp & Dohme Isoindolinone PDE10 INHIBITORS
NO3175985T3 (https=) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
EP2729007A1 (de) 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
WO2013076590A1 (en) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Benzothiazine compounds as h3 receptor ligands
CN116368130A (zh) * 2020-08-28 2023-06-30 金橘生物科技公司 杂环化合物及其用途
US12496297B1 (en) * 2020-10-23 2025-12-16 Washington University Compositions of autophagy modulating agents and uses thereof
CN115819347B (zh) * 2022-11-14 2024-08-30 暨明医药科技（苏州）有限公司 一种1-烷基-3-溴吡唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US6541499B1 (en) * 1997-05-01 2003-04-01 Eli Lilly And Company Antithrombotic agents
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
ES2540987T3 (es) * 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CN101107231A (zh) * 2005-01-21 2008-01-16 先灵公司 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103649056A (zh) * 2011-05-10 2014-03-19 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
CN103649056B (zh) * 2011-05-10 2016-04-27 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
CN105254554A (zh) * 2014-07-14 2016-01-20 南开大学 一种制备异吲哚啉酮类化合物的方法
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法
CN115551593A (zh) * 2020-04-08 2022-12-30 雷密克斯医疗公司 用于调节剪接的化合物和方法

Also Published As

Publication number Publication date
WO2009036144A1 (en) 2009-03-19
NI201000036A (es) 2010-08-13
CR11303A (es) 2010-03-18
JP2010539180A (ja) 2010-12-16
BRPI0817061A2 (pt) 2015-03-24
EA201000316A1 (ru) 2010-10-29
MX2010002760A (es) 2010-04-01
CA2699384A1 (en) 2009-03-19
KR20100054856A (ko) 2010-05-25
MA31699B1 (fr) 2010-09-01
EP2200989A1 (en) 2010-06-30
TW200927114A (en) 2009-07-01
DOP2010000079A (es) 2010-03-31
AR068423A1 (es) 2009-11-18
CL2008002726A1 (es) 2008-10-10
PE20090651A1 (es) 2009-05-28
ECSP10010025A (es) 2010-08-31
AP2010005202A0 (en) 2010-04-30
ZA201001751B (en) 2010-11-24
US20090069300A1 (en) 2009-03-12
PA8795701A1 (es) 2009-04-23
AU2008298926A1 (en) 2009-03-19
TN2010000105A1 (fr) 2011-09-26
CO6300955A2 (es) 2011-07-21

Similar Documents

Publication Publication Date Title
CN101848896A (zh) 作为组胺-3拮抗剂的异喹啉基和异吲哚啉基衍生物
CN101484420B (zh) 作为5-ht6调节剂的吲哚
CN111170999B (zh) Egfr抑制剂及其制备和应用
AU2008298983A1 (en) Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists
KR20070026390A (ko) 화합물 및 사용방법
KR102101047B1 (ko) １－［ｍ－카르복사미도（헤테로）아릴－메틸］－헤테로시클릴－카르복사미드 유도체
MX2014008647A (es) Compuesto de pirazin-carboxamida.
CN112673000B (zh) 作为受体相互作用蛋白激酶1抑制剂(ripk1)的1h-吲唑甲酰胺
CN108349935B (zh) 吡咯烷衍生物
EP2504316A1 (en) Heterocylic compounds as antagonists of the orexin receptors
US9255090B2 (en) Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
CN102282139B (zh) 作为nk3受体拮抗剂的哌啶衍生物
HK1144815A (en) Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
HK1143583A (en) Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1144815

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100929

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1144815

Country of ref document: HK